---
$id: https://graph.org.ai/products/commodity/51111858
$type: Product
source: UNSPSC
code: "51111858"
title: "Liarozole"
class: "51111800"
classTitle: "Hormones and antihormones"
family: "51110000"
familyTitle: "Antineoplastic agents"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Liarozole

**UNSPSC Code**: 51111858
**Class**: [Hormones and antihormones](Hormones and antihormones.mdx)
**Family**: [Antineoplastic agents](../Antineoplastic agents.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes a non-steroidal aromatase inhibitor with the molecular formula C17H13ClN4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K0Q29TGV9Y, chemically known as 1h-benzimidazole, 5-((3-chlorophenyl)-1h-imidazol-1-ylmethyl)- but generally known as liarozole, which bears US NIH Compound Identifier 60652. European Medicines Agency schedules Liarozole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14356MIG. The term LIAROZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). Most nations schedule liarozole under HS 29332990 and SITC 51573. As of Q4 2014, LIAROZOLE remains the US FDA Preferred Term for this commodity. Liarozole bears US NLM identifiers UMLS ID C0165479 and NCI Concept Code C1433. SMILES: CLC1CC(C(N2CCNC2)C2CC3[NH]CNC3CC2)CCC1.

